Diversify Advisory Services LLC Invests $2.77 Million in Halozyme Therapeutics, Inc. $HALO

Diversify Advisory Services LLC purchased a new stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO) in the 2nd quarter, Holdings Channel.com reports. The institutional investor purchased 33,976 shares of the biopharmaceutical company’s stock, valued at approximately $2,768,000.

Several other institutional investors have also modified their holdings of the business. Measured Wealth Private Client Group LLC grew its stake in Halozyme Therapeutics by 51.5% during the 4th quarter. Measured Wealth Private Client Group LLC now owns 365 shares of the biopharmaceutical company’s stock worth $25,000 after purchasing an additional 124 shares in the last quarter. Larson Financial Group LLC increased its holdings in Halozyme Therapeutics by 3,118.2% during the 3rd quarter. Larson Financial Group LLC now owns 354 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 343 shares during the period. MidFirst Bank acquired a new stake in Halozyme Therapeutics in the 2nd quarter valued at about $27,000. Mitsubishi UFJ Asset Management Co. Ltd. acquired a new stake in Halozyme Therapeutics in the 2nd quarter valued at about $28,000. Finally, Harbour Investments Inc. boosted its stake in shares of Halozyme Therapeutics by 152.5% in the 4th quarter. Harbour Investments Inc. now owns 616 shares of the biopharmaceutical company’s stock valued at $41,000 after buying an additional 372 shares during the period. Institutional investors and hedge funds own 97.79% of the company’s stock.

Halozyme Therapeutics Stock Up 1.8%

HALO stock opened at $104.89 on Wednesday. The company has a fifty day moving average price of $80.97 and a 200 day moving average price of $73.02. Halozyme Therapeutics, Inc. has a 12 month low of $61.22 and a 12 month high of $105.11. The company has a market cap of $11.91 billion, a price-to-earnings ratio of 31.31, a price-to-earnings-growth ratio of 0.40 and a beta of 0.85. The company has a debt-to-equity ratio of 13.50, a current ratio of 2.71 and a quick ratio of 2.31.

Halozyme Therapeutics (NASDAQ:HALO) last posted its quarterly earnings data on Thursday, August 6th. The biopharmaceutical company reported $2.28 EPS for the quarter, beating the consensus estimate of $1.79 by $0.49. Halozyme Therapeutics had a return on equity of 260.98% and a net margin of 24.86%.The firm had revenue of $481.00 million during the quarter, compared to the consensus estimate of $402.28 million. During the same period in the prior year, the business earned $1.54 EPS. The firm’s revenue was up 47.7% compared to the same quarter last year. Halozyme Therapeutics has set its FY 2026 guidance at 8.650-9.000 EPS. Sell-side analysts expect that Halozyme Therapeutics, Inc. will post 7.77 earnings per share for the current year.

Insider Activity at Halozyme Therapeutics

In related news, CEO Helen Torley sold 1,923 shares of the firm’s stock in a transaction that occurred on Wednesday, July 8th. The stock was sold at an average price of $79.77, for a total value of $153,397.71. Following the completion of the transaction, the chief executive officer directly owned 767,780 shares of the company’s stock, valued at $61,245,810.60. This trade represents a 0.25% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Bernadette Connaughton sold 1,626 shares of Halozyme Therapeutics stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $102.80, for a total value of $167,152.80. Following the transaction, the director owned 40,418 shares of the company’s stock, valued at $4,154,970.40. This represents a 3.87% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 44,103 shares of company stock worth $3,142,896 over the last 90 days. Company insiders own 2.50% of the company’s stock.

Analyst Ratings Changes

Several research analysts have commented on the stock. Citigroup reiterated a “market outperform” rating on shares of Halozyme Therapeutics in a report on Friday, August 7th. Benchmark restated a “buy” rating on shares of Halozyme Therapeutics in a report on Tuesday, July 21st. Wells Fargo & Company lifted their price objective on shares of Halozyme Therapeutics from $75.00 to $95.00 and gave the stock an “equal weight” rating in a research report on Friday, August 7th. TD Cowen boosted their target price on shares of Halozyme Therapeutics from $96.00 to $105.00 and gave the stock a “buy” rating in a research note on Friday, August 7th. Finally, Leerink Partners raised Halozyme Therapeutics from a “market perform” rating to an “outperform” rating and increased their target price for the company from $83.00 to $110.00 in a report on Friday, August 7th. Nine analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $91.20.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.